| ENZ-ABS327-0100 | 100 µg | 486.00 USD |  |
||
| Do you need bulk/larger quantities? | |||||
| Alternative Name: | Ki-1, TNFRSF 8 |
| Clone: | rKi-1/779 |
| Host: | Mouse |
| Isotype: | lgG1κ |
| Immunogen: | Recombinant full length human CD30. |
| UniProt ID: | P28908 |
| Species reactivity: | Human |
| Applications: | Flow Cytometry, IF, IHC (PS) |
| Recommended Dilutions/Conditions: | Flow Cytometry (0.5-1 µg/106 cells in 0.1 mL) Immunofluorescence (1-2 µg/mL) Immunohistochemistry (formalin-fixed paraffin sections) (0.5-1 µg/mL for 30 min at RT) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
| Application Notes: | This mAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. |
| Purity Detail: | Protein G affinity purified. |
| Formulation: | Liquid. In 1X PBS containing 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide. |
| Shipping: | Blue Ice |
| Long Term Storage: | +4°C |
| Scientific Background: | CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkin's disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. About one third of the CD30/Ki-1 positive lymphomas lack the leukocyte common antigen (CD45). |
| Regulatory Status: | RUO - Research Use Only |
 |
|
| Download as PDF | |
